Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease
-
Published:2024-09
Issue:
Volume:
Page:
-
ISSN:0165-6147
-
Container-title:Trends in Pharmacological Sciences
-
language:en
-
Short-container-title:Trends in Pharmacological Sciences
Author:
Hubert Sandra,
Kök-Carrière Ayrin,
De Ceuninck FrédéricORCID
Reference10 articles.
1. The Pharmacology of Two Novel Long-Acting Phosphodiesterase 3/4 Inhibitors, RPL554 [9,10-Dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-Dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]
2. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials;Franciosi;Lancet Respir. Med.,2013
3. A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD;Singh;Respir. Res.,2020
4. Symptom improvement following treatment with the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in patients with moderate to severe COPD - a detailed analysis;Watz;Int. J. Chron. Obstruct. Pulmon. Dis.,2020
5. The phosphodiesterase inhibitor ensifentrine reduces production of proinflammatory mediators in well differentiated bronchial epithelial cells by inhibiting PDE4;Turner;J. Pharmacol. Exp. Ther.,2020